Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Andrew Branangan, MD, PhD
CONTACT
Lead
Massachusetts General Hospital
With
This is an open label phase II study that will enroll 24 patients with relapsed or refractory Waldenstrom's macroglobulinemia after one or more lines of systemic therapy for WM, including an anti-CD20 monoclonal antibody-containing regimen or a BTK inhibitor. This research study is evaluating a less frequent and shorter dosing schedule of teclistamab compared to the approved dosing schedule for individuals with multiple myeloma, which includes more frequent dosing in early treatment cycles and continuing to receive teclistamab until disease progression or unacceptable side effects occur. Johnson \& Johnson is supporting this research study by providing the study drug, teclistamab, and funding for the clinical trial activities. The U.S. Food and Drug Administration (FDA) has not approved teclistamab for relapsed or refractory Waldenstrom's macroglobulinemia, but it has been approved to treat other types of multiple myeloma that has come back or been difficult to treat. Teclistamab is a type of antibody-based medication that attaches to both cancer cells and the body's T cells (a type of immune cell). By connecting the two, teclistamab bring T cells close enough to the cancer cells so they can activate and kill the cancer cells directly, without needing usual immune-system signals.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
